ASCO 2017 - Melanoma brain mets: nivolumab+ipilimumab deliver promising phase 2 results

Access to the full content of this site is available only to registered healthcare professionals. Register to read more


  • At a maximum tolerated dose of nivolumab (Opdivo) 3 mg/kg or 1 mg/kg+ipilimumab (Yervoy) 3 mg/kg, 42% of patients in the combined group achieved best intracranial response vs 20% in the single groups of this phase 2 trial.

Why this matters

  • Previous trials excluded patients ...